144 related articles for article (PubMed ID: 38063869)
1. Relationship between plasma NFL and disease progression in Parkinson's disease: a prospective cohort study.
Ou R; Liu K; Lin J; Yang T; Xiao Y; Wei Q; Hou Y; Li C; Zhang L; Jiang Z; Zhao B; Chen X; Song W; Wu Y; Shang H
J Neurol; 2024 Apr; 271(4):1837-1843. PubMed ID: 38063869
[TBL] [Abstract][Full Text] [Related]
2. Blood NfL: A biomarker for disease severity and progression in Parkinson disease.
Lin CH; Li CH; Yang KC; Lin FJ; Wu CC; Chieh JJ; Chiu MJ
Neurology; 2019 Sep; 93(11):e1104-e1111. PubMed ID: 31420461
[TBL] [Abstract][Full Text] [Related]
3. Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson's disease.
Ng ASL; Tan YJ; Yong ACW; Saffari SE; Lu Z; Ng EY; Ng SYE; Chia NSY; Choi X; Heng D; Neo S; Xu Z; Keong NCH; Tay KY; Au WL; Tan LCS; Tan EK
Mol Neurodegener; 2020 Jun; 15(1):33. PubMed ID: 32503574
[TBL] [Abstract][Full Text] [Related]
4. Association of serum neurofilament light chain and glial fibrillary acidic protein levels with cognitive decline in Parkinson's disease.
Mao S; Teng X; Li Z; Zu J; Zhang T; Xu C; Cui G
Brain Res; 2023 Apr; 1805():148271. PubMed ID: 36754139
[TBL] [Abstract][Full Text] [Related]
5. Serum neurofilament is associated with motor function, cognitive decline and subclinical cardiac damage in advanced Parkinson's disease (MARK-PD).
Niemann L; Lezius S; Maceski A; Leppert D; Englisch C; Schwedhelm E; Zeller T; Gerloff C; Kuhle J; Choe CU
Parkinsonism Relat Disord; 2021 Sep; 90():44-48. PubMed ID: 34352610
[TBL] [Abstract][Full Text] [Related]
6. Plasma NfL, clinical subtypes and motor progression in Parkinson's disease.
Pilotto A; Imarisio A; Conforti F; Scalvini A; Masciocchi S; Nocivelli S; Turrone R; Gipponi S; Cottini E; Borroni B; Rizzetti MC; Pizzi M; Bonanni L; Sturchio A; Espay AJ; Zetterberg H; Ashton NJ; Hye A; Padovani A
Parkinsonism Relat Disord; 2021 Jun; 87():41-47. PubMed ID: 33964785
[TBL] [Abstract][Full Text] [Related]
7. Integrated Plasma and Neuroimaging Biomarkers Associated with Motor and Cognition Severity in Parkinson's Disease.
Chen CH; Lee BC; Lin CH
J Parkinsons Dis; 2020; 10(1):77-88. PubMed ID: 31868681
[TBL] [Abstract][Full Text] [Related]
8. Serum Neurofilament Dynamics Predicts Cognitive Progression in de novo Parkinson's Disease.
Ma LZ; Zhang C; Wang H; Ma YH; Shen XN; Wang J; Tan L; Dong Q; Yu JT
J Parkinsons Dis; 2021; 11(3):1117-1127. PubMed ID: 33935105
[TBL] [Abstract][Full Text] [Related]
9. Serum neurofilament light chain levels reflect cortical neurodegeneration in de novo Parkinson's disease.
Sampedro F; Pérez-González R; Martínez-Horta S; Marín-Lahoz J; Pagonabarraga J; Kulisevsky J
Parkinsonism Relat Disord; 2020 May; 74():43-49. PubMed ID: 32334380
[TBL] [Abstract][Full Text] [Related]
10. Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease.
Aamodt WW; Waligorska T; Shen J; Tropea TF; Siderowf A; Weintraub D; Grossman M; Irwin D; Wolk DA; Xie SX; Trojanowski JQ; Shaw LM; Chen-Plotkin AS
Mov Disord; 2021 Dec; 36(12):2945-2950. PubMed ID: 34480363
[TBL] [Abstract][Full Text] [Related]
11. Serum NFL levels predict progression of motor impairment and reduction in putamen dopamine transporter binding ratios in de novo Parkinson's disease: An 8-year longitudinal study.
Ye R; Locascio JJ; Goodheart AE; Quan M; Zhang B; Gomperts SN
Parkinsonism Relat Disord; 2021 Apr; 85():11-16. PubMed ID: 33639572
[TBL] [Abstract][Full Text] [Related]
12. Dissociable contribution of plasma NfL and p-tau181 to cognitive impairment in Parkinson's disease.
Pagonabarraga J; Pérez-González R; Bejr-Kasem H; Marín-Lahoz J; Horta-Barba A; Martinez-Horta S; Aracil-Bolaños I; Sampedro F; Campolongo A; Rivas E; Puig-Davi A; Ruiz-Barrios I; Pérez-Pérez J; Pascual-Sedano B; Kulisevsky J
Parkinsonism Relat Disord; 2022 Dec; 105():132-138. PubMed ID: 35752549
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid neurofilament dynamic profiles predict cognitive progression in individuals with
Sheng ZH; Ma LZ; Liu JY; Ou YN; Zhao B; Ma YH; Tan L
Front Aging Neurosci; 2022; 14():1061096. PubMed ID: 36589544
[TBL] [Abstract][Full Text] [Related]
14. Development of an assay of plasma neurofilament light chain utilizing immunomagnetic reduction technology.
Liu HC; Lin WC; Chiu MJ; Lu CH; Lin CY; Yang SY
PLoS One; 2020; 15(6):e0234519. PubMed ID: 32530970
[TBL] [Abstract][Full Text] [Related]
15. Plasma glial fibrillary acidic protein as a biomarker of disease progression in Parkinson's disease: a prospective cohort study.
Lin J; Ou R; Li C; Hou Y; Zhang L; Wei Q; Pang D; Liu K; Jiang Q; Yang T; Xiao Y; Zhao B; Chen X; Song W; Yang J; Wu Y; Shang H
BMC Med; 2023 Nov; 21(1):420. PubMed ID: 37932720
[TBL] [Abstract][Full Text] [Related]
16. Elevated α-synuclein and NfL levels in tear fluids and decreased retinal microvascular densities in patients with Parkinson's disease.
Lin CW; Lai TT; Chen SJ; Lin CH
Geroscience; 2022 Jun; 44(3):1551-1562. PubMed ID: 35484471
[TBL] [Abstract][Full Text] [Related]
17. Neurofilament light predicts worse nonmotor symptoms and depression in Parkinson's disease.
Urso D; Batzu L; Logroscino G; Ray Chaudhuri K; Pereira JB
Neurobiol Dis; 2023 Sep; 185():106237. PubMed ID: 37499883
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of plasma levels of NFL, GFAP, UCHL1 and tau as Parkinson's disease biomarkers using multiplexed single molecule counting.
Youssef P; Hughes L; Kim WS; Halliday GM; Lewis SJG; Cooper A; Dzamko N
Sci Rep; 2023 Mar; 13(1):5217. PubMed ID: 36997567
[TBL] [Abstract][Full Text] [Related]
19. Serum Neurofilament Light Chain as a Marker of Progression in Parkinson's Disease: Long-Term Observation and Implications of Clinical Subtypes.
Ygland Rödström E; Mattsson-Carlgren N; Janelidze S; Hansson O; Puschmann A
J Parkinsons Dis; 2022; 12(2):571-584. PubMed ID: 34806619
[TBL] [Abstract][Full Text] [Related]
20. CSF NFL in a Longitudinally Assessed PD Cohort: Age Effects and Cognitive Trajectories.
Lerche S; Wurster I; Röben B; Zimmermann M; Machetanz G; Wiethoff S; Dehnert M; Rietschel L; Riebenbauer B; Deuschle C; Stransky E; Lieplt-Scarfone I; Gasser T; Brockmann K
Mov Disord; 2020 Jul; 35(7):1138-1144. PubMed ID: 32445500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]